Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
Andy Studna
Advertisement
Articles by Andy Studna
Advertisement
Latest Updated Articles
Efsitora Alfa, Eli Lilly’s Once Weekly Insulin, Has Positive Topline Results in Two TrialsPublished: September 6th 2024 | Updated:
Teal Health Granted Breakthrough Device Designation for Self-Collect Cervical Cancer Screening DevicePublished: May 14th 2024 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
New ACS Guideline Endorses Self-Collected HPV Tests for Cervical Cancer Screening
2
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option
3
Hepatitis B Foundation President Discusses ACIP Hepatitis B Birth Dose Recommendation
4
Why Nearly 1 in 5 Women Experiencing Perimenopause Have Wanted to Leave Their Jobs With Bruce Dorr, MD, URPS, IFM-CP
5
